Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Probiotics  COVID-19 treatment studies for Probiotics  C19 studies: Probiotics  Probiotics   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Ventilation 65% Improvement Relative Risk Antibody formation 67% c19early.org/k Zhang et al. NCT04581018 Probiotics LATE TREATMENT Is late treatment with probiotics beneficial for COVID-19? Retrospective 55 patients in China No significant difference in outcomes Zhang et al., J. Gastroenterology and Hepatology, doi:10.1111/jgh.15796 Favors probiotics Favors control
Gut microbiota-derived synbiotic formula (SIM01) as a novel adjuvant therapy for COVID-19: An open-label pilot study
Zhang et al., Journal of Gastroenterology and Hepatology, doi:10.1111/jgh.15796, NCT04581018 (history)
Zhang et al., Gut microbiota-derived synbiotic formula (SIM01) as a novel adjuvant therapy for COVID-19: An open-label pilot.., Journal of Gastroenterology and Hepatology, doi:10.1111/jgh.15796, NCT04581018
Mar 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Pilot study of probiotic SIM01 with 25 consecutive COVID-19 patients in Hong Kong and 30 control patients treated by a different team during the same time period, showing improved antibody formation, reduced viral load and pro-inflammatory responses, and improvements for gut dysbiosis. SIM01 contains bifidobacteria strains, galactooligosaccharides, xylooligosaccharide, and resistant dextrin (derived from metagenomic databases of COVID-19 patients and healthy patients).
The immune effects of probiotics are strain-specific.
risk of mechanical ventilation, 64.7% lower, RR 0.35, p = 1.00, treatment 0 of 25 (0.0%), control 1 of 30 (3.3%), NNT 30, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of no antibody formation, 67.3% lower, RR 0.33, p = 0.06, treatment 3 of 25 (12.0%), control 11 of 30 (36.7%), NNT 4.1.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Zhang et al., 2 Mar 2022, retrospective, China, peer-reviewed, 12 authors, trial NCT04581018 (history).
Contact: siewchienng@cuhk.edu.hk, fklchan@cuhk.edu.hk.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperProbioticsAll
Abstract: bs_bs_banner doi:10.1111/jgh.15796 CLINICAL TRIAL Gut microbiota-derived synbiotic formula (SIM01) as a novel adjuvant therapy for COVID-19: An open-label pilot study Lin Zhang,*,†,‡1 Zhilu Xu,*,†,‡1 Joyce W Y Mak,*,†,‡ Kai Ming Chow,† Grace Lui,†,§ Timothy C M Li,† ¶ † Chun Kwok Wong, Paul K S Chan,** Jessica Y L Ching, Yasuhiro Fujiwara,†† Francis K L Chan*,†,‡ and ,†,‡ Siew C Ng* *Microbiota I-Center (MagIC), †Department of Medicine and Therapeutics, Faculty of Medicine, ‡State Key Laboratory of Digestive Disease, Institute of Digestive Disease, Li Ka Shing Institute of Health Sciences, Faculty of Medicine, §Stanley Ho Centre for Emerging Infectious Diseases, Faculty of Medicine, ¶ Department of Chemical Pathology, Faculty of Medicine, **Department of Microbiology, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China; and ††Department of Gastroenterology, Osaka City University Graduate School of Medicine, Osaka, Japan Key words immunity, microbiota, probiotics, SARS-CoV-2. Accepted for publication 3 February 2022. Correspondence Siew C Ng and Francis K L Chan, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China. Email: siewchienng@cuhk.edu.hk; fklchan@cuhk.edu.hk Declaration of conflict of interest: Prof. Siew Ng and Prof. Francis Chan report serving as founder member for GenieBiome Limited. Prof. Siew Ng also has served as advisory board member for Pfizer, Ferring, Janssen, Abbvie and speaker for Ferring, Tillotts, Menarini, Janssen, Abbvie, and Takeda. She has received research grants from Olympus, Ferring and Abbvie. Prof. Francis Chan has served as the Director & Board member of CUHK Medical Centre Limited and First Director of the Board of Directors for CUHK Multi-Scale Medical Robotics Centre Limited. He also has served as advisor and lecture speaker for Eisai Co. Ltd, AstraZeneca, Pifzer Inc, Takeda Pharmaceutical Co., Takeda (China) Holdings Co. Ltd. Prof. Siew Ng, Prof. Francis Chan, and Dr Zhilu Xu are inventors of patent applications for “Composition for Improving Immunity” (CN202010657312.5, CN202011259564.9, CN202110223880.9, PCT/CN2021/090531, and TW110115155). Prof. Siew Ng and Prof. Francis Chan are inventors of patent applications for Abstract Background and Aim: Gut dysbiosis is associated with immune dysfunction and severity of COVID-19. Whether targeting dysbiosis will improve outcomes of COVID-19 is unknown. This study aimed to assess the effects of a novel gut microbiota-derived synbiotic formula (SIM01) as an adjuvant therapy on immunological responses and changes in gut microbiota of hospitalized COVID-19 patients. Methods: This was an open-label, proof-of-concept study. Consecutive COVID-19 patients admitted to an infectious disease referral center in Hong Kong were given a novel formula of Bifidobacteria strains, galactooligosaccharides, xylooligosaccharide, and resistant dextrin (SIM01). The latter was derived from metagenomic databases of COVID-19 patients and healthy population. COVID-19 patients who were admitted under another independent infectious disease team during the same period without receiving SIM01 acted as controls. All patients received standard treatments for COVID-19 according to the hospital protocol. We assessed antibody response, plasma proinflammatory markers, nasopharyngeal SARS-CoV-2 viral load, and fecal microbiota profile from admission up to week 5. Results: Twenty-five consecutive COVID-19 patients received..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit